Invasive pneumococcal disease in Australia, 2011 and 2012
DOI:
https://doi.org/10.33321/cdi.2016.40.22Keywords:
invasive pneumococcal disease, communicable disease surveillance, epidemiology, annual report, AustraliaAbstract
In Australia, there were 1,883 cases (8.3 per 100,000 population) of invasive pneumococcal disease (IPD) notified to the National Notifiable Diseases Surveillance System (NNDSS) in 2011 and 1,823 cases (8.0 per 100,000) in 2012. The overall rate of IPD in Indigenous Australians was 9 times the rate of IPD in non-Indigenous Australians in 2011 and 7 times in 2012. Following the July 2011 introduction of the 13-valent pneumococcal conjugate vaccine (13vPCV) to the National Immunisation Program, rates of IPD in children aged less than 5 years decreased from 19.5 per 100,000 in 2011 to 12.6 per 100,000 in 2012. In Indigenous adults aged 50 years or over the rates of IPD caused by serotypes included in the 23-valent pneumococcal polysaccharide vaccine (23vPPV) continued to increase in both 2011 (47.2 per 100,000) and 2012 (51.2 per 100,000). The rates of IPD in non-Indigenous adults aged 65 years or over caused by serotypes included in the 23vPPV also increased in 2011 (10.1 per 100,000) and 2012 (11.2 per 100,000). There were 134 deaths attributable to IPD in 2011 and 126 in 2012, although it should be noted that deaths may be under-reported. The number of invasive pneumococcal isolates with reduced penicillin susceptibility remained low and reduced susceptibility to ceftriaxone/cefotaxime continued to be rare. Commun Dis Intell 2016;40(2):E267–E284.
Downloads
References
World Health Organization. Pneumococcal disease. Accessed on 19 January. Available from: http://www.who.int/ith/diseases/pneumococcal/en/
Chiu C, Dey A, Wang H, Menzies R, Deeks S, Mahajan D, et al. Vaccine preventable diseases in Australia, 2005 to 2007. Commun Dis Intell 2010;34(Suppl):S1–S172.
Australian Technical Advisory Group on Immunisation. The Australian Immunisation Handbook. 10th edn. Canberra, Australia: National Health and Medical Research Council and the Department of Health; 2013.
National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases. Significant events in pneumococcal vaccination practice in Australia. 2015. Accessed on 26 May 2015. Available from: http://ncirs.edu.au/immunisation/history/Pneumococcal-history-March-2015.pdf
Australian Government Department of Health. Invasive pneumococcal disease reports. Accessed on 26 May 2015. Available from: http://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-ipd-reports.htm
Australian Bureau of Statistics. Australian Demographic Statistics, June 2013. ABS cat no. 3101.0 Canberra; Australian Bureau of Statistics; 2013.
Public Health Laboratory Network. Pneumococcal Disease (Invasive) Laboratory Case Definition. 2001. Accessed on 19 January 2016. Available from: http://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-phlncd-pneumococcal.htm
Communicable Diseases Network Australia. Pneumococcal disease (invasive) case definition. 2004. Accessed on 9 November 2015. Available from: http://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd_pnuemo.htm
Lai JY, Cook H, Yip TW, Berthelsen J, Gourley S, Krause V, et al. Surveillance of pneumococcal serotype 1 carriage during an outbreak of serotype 1 invasive pneumococcal disease in central Australia 2010–2012. BMC Infect Dis 2013;13:409.
Staples M, Graham RM, Jennison AV, Ariotti L, Hicks V, Cook H, et al. Molecular characterization of an Australian serotype 1 Streptococcus pneumoniae outbreak. Epidemiol Infect 2015;143(2):325–333.
Choi YH, Jit M, Gay N, Andrews N, Waight PA, Melegaro A, et al. 7-valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement? PLoS One 2011;6(10):e26190.
Steens A, Bergsaker MA, Aaberge IS, Ronning K, Vestrheim DF. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine 2013;31(52):6232–6238.
Pilishvili T, Lexau C, Farley M, Hadler J, Harrison L, Bennett N, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine J Infect Dis 2010;201(1):32–41.
Cooper D YX, Sidhu M, Nahm MH, Philip F, Jansen KU. The 13-valent pneumococcal vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine 2011;29(4):7207–7211.
Demczuk WH, Martin I, Griffith A, Lefebvre B, McGeer A, Lovgren M, et al. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010–2012. Can J Microbiol 2013;59(12):778–788.
Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalf L, Zancolli M, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a post-licensure indirect cohort study. Lancet Infect Dis 2014;14(9):839–846.
Esposito S, Principi N. Impacts of the 13-valent pneumococcal conjugate vaccine in children. J Immunol Res 2015;2015:591580. doi: 10.1155/2015/591580.
Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multi-site, population-based surveillance. Lancet Infect Dis 2015;15(3):301–309.
Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008(1):CD000422.
Vila-Corcoles A, Ochoa-Gondar O, Guzman JA, Rodriguez-Blanco T, Salsench E, Fuentes CM, et al. Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older. BMC Infect Dis 2010;10:73.
-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec 2008;83(42):373–384.
Menzies R, Turnour C, Chiu C, McIntyre P. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander People, Australia, 2003 to 2006. Commun Dis Intell 2008;32(Suppl):S1–S67.
Harboe ZB, Dalby T, Weinberger DM, Benfield T, Molbak K, Slotved HC, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis 2014;59(8):1066–1073.
Musher DM, Sexton DJ, Thorner AR. Resistance of Streptococcus pneumoniae to beta-lactam antibiotics. [online] UpToDate 2014.
Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae 2012. Accessed on 25 may 2015. Available from: http://www.cdc.gov/abcs/reports-findings/survreports/spneu12.html
Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae, 2011. Accessed on 25 May 2015. Available from: http://www.cdc.gov/abcs/reports-findings/survreports/spneu11.htm
Downloads
Published
How to Cite
License
Copyright (c) 2016 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
